Rising India (RSII) Sees Investor Interest Rise on their CBD Therapy

Alerts
Share


Share this alert above

(NEW YORK)–Rising India, Inc. (OTC:RSII), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, sees investor interest rise on trial launch of cancer therapy drug Cannophen™.

One of the first products to draw attention of traders to RSII was their TSW product for muscle and joint pain, back pain, neuropathy/nerve pain and arthritis. TSW Pain, a topical pain relief cream for muscle and joint relief, is currently under testing to meet FDA requirements.

Sponsor: AppSwarm (OTC:SWRM)

With the explosive epidemic of opioid addiction sweeping this country any alternative pain therapy away from these awful medications is sure to catch attention of investors, and TSW Pain is something to watch.

In addition to that the Company is also in testing phase with a Scar Peptide Serum to helps with scare and tissue repair.

Related: CIIX Receives CFDA Approval for its Hemp Infused Skin Care Line

But what really set RSII on fire in recent weeks was news that they will be partnering with PAO Group (OTC:PAOG) to offer a free trial of Cannophen™ to patients in the state of Ohio.

Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.

CBD Cancer Research

Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.

Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. One notable study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.

There can be no doubt that RSII has caught the attention of traders to their stock, which closed Friday at around $0.02 per share. RSII has been one of the most discussed plays among traders in the past few trading sessions, and sure to say any additional news from the Company will be closely watched.

Register for Updates

Since RSII story is just beginning to unfold, Wall Street Newscast will be providing ongoing coverage on their anticipated roll-out of Cannophen, and investors interested in getting updates on this, or other alerts within the small cap sector can register to our free investor mailing list at
http://www.wallstreetnewscast.com/investors/


Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was not compensated for this emdia alert. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities.